Antibodies

27 June 2015

Roche’s Perjeta recommended for approval in EU for use before surgery in HER2-positive early breast cancer

26 June 2015

SIMPONI® Receives European Commission Approval for Treatment of Non-radiographic Axial Spondyloarthritis

26 June 2015

Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

26 June 2015

Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX® (rFIXFc) Marketing Authorization Application

25 June 2015

Vaccinex, Inc. Announces the Initiation of a Phase 2 Clinical Trial of Its Investigational VX15/2503 Antibody in Huntington’s Disease (the SIGNAL Trial)

24 June 2015

Biotest regains rights to Tregalizumab (BT-061)

23 June 2015

Positive Interim Data from Phase I/II study of Chugai’s Bispecific Antibody “ACE910” Presented at the ISTH 2015 Congress

20 June 2015

Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine

19 June 2015

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients

19 June 2015

Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care

18 June 2015

Updated Results From Phase 2 Clinical Trial of TG-1101 (Ublituximab) in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety Profile in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)

18 June 2015

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson’s Disease

18 June 2015

ImmunoGen’s IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma

18 June 2015

Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study

17 June 2015

Nordic Nanovector: Updated Results of Ongoing Phase 1/2 Study with Betalutin™ in Relapsed CD37+ Non-Hodgkin Lymphoma Patients

16 June 2015

Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M

15 June 2015

ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire

15 June 2015

Teva Announces FDA Acceptance of the Biologics License Application for Reslizumab

15 June 2015

Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan

13 June 2015

Prothena’s NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association

13 June 2015

GSK announces outcome of US FDA Advisory Committee recommending approval of mepolizumab for the treatment of adults with severe asthma

11 June 2015

Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis

11 June 2015

Studies Show Psoriasis Patients Achieved Significant Levels of Skin Clearance and Improved Quality of Life after 12 Weeks of Ixekizumab Treatment

10 June 2015

EPIRUS Biopharmaceuticals Presents New BOW015 (Infliximab Biosimilar) Data at the European League Against Rheumatism Annual Congress (EULAR 2015)

10 June 2015

Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

10 June 2015

FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis

10 June 2015

Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints

10 June 2015

Biogen and Samsung Bioepis Announce New Data for Three Anti-TNF Biosimilar Development Candidates at EULAR 2015 Congress

10 June 2015

Prothena Announces First Human Dosed in Phase 1 Study of PRX003 for the Treatment of Psoriasis and Other Inflammatory Diseases

10 June 2015

New results from first real-world study show comparable effectiveness and safety of Hospira’s Inflectra™ (infliximab) in patients with rheumatic diseases switched from reference infliximab, Remicade™

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ustekinumab (Stelara) Biosimilars Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

PD-1 Agonists Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

PSMA-Targeted Therapy Pipeline Review